NEWS

Drs. Shrey Kohli, Berend Isermann, and team report in Nature Communications that the PAR1-targeting parmodulin ML161 (aka Parmodulin 2)...

Function Therapeutics is pleased to welcome Dr. Paul Ornstein as its VP of Preclinical Development. Paul trained with a series of...

Function Therapeutics, Inc. received official notice of a U.S. Department of Defense Peer Reviewed Medical Research Program Discovery...